Jonathan Langdown

This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Janssen Pharmaceuticals, Inc.. Active years: 2016-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Langdown. Retrieved from https://idiyas.com/inventor/jonathan-langdown

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 25.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

8 out of 161

Janssen Pharmaceuticals, Inc.

patents

Years Active: 2016-2021

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11155637 - Thrombin-binding antibody molecules and uses thereof (2021-10-26),

2. 10370454 - Thrombin-binding antibody molecules and uses thereof (2019-08-06),

3. 10287363 - Thrombin-binding antibody molecules and uses thereof (2019-05-14),

4. 9988463 - Thrombin-binding antibody molecules and uses thereof (2018-06-05),

5. 9988461 - Thrombin-binding antibody molecules and uses thereof (2018-06-05),

6. 9605082 - Thrombin-binding antibody molecules and uses thereof (2017-03-28),

7. 9518129 - Thrombin-binding antibody molecules and uses thereof (2016-12-13),

8. 9518128 - Thrombin-binding antibody molecules (2016-12-13),

Title: The Innovations of Jonathan Langdown

Introduction

Jonathan Langdown is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 8 patents to his name, Langdown's work has the potential to impact medical treatments significantly.

Latest Patents

One of Langdown's latest patents is focused on thrombin-binding antibody molecules and their uses. This invention relates to isolated antibodies that recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism, and other conditions mediated by thrombin. This innovative approach could lead to safer therapeutic options for patients at risk of thrombotic events.

Career Highlights

Langdown has established himself as a key figure in the biotechnology sector. His work at Janssen Pharmaceuticals, Inc. has allowed him to collaborate with leading experts in the field. His innovative research has garnered attention and respect from peers and industry leaders alike.

Collaborations

Some of Langdown's notable coworkers include Trevor Baglin and James Andrew Huntington. Their collaborative efforts have contributed to advancing research in the field of thrombin-related therapies.

Conclusion

Jonathan Langdown's contributions to biotechnology through his innovative patents and collaborations highlight his importance in the field. His work continues to pave the way for advancements in medical treatments, particularly in the area of thrombin inhibition.

Profile summary based on public USPTO records.